// App-Quantinova.ai

1315 : Nanoparticles targeting RAF/ERK-driven cell-autonomous resistance to sorafenib for effective treatment of hepatocellular carcinoma

Researchers

Presenter

  • Yunching Chen

Principal Investigators

  • Ya-Chi Liu

  • Ts-Ting Lin

  • Rakesh Ramjiawan

  • Dan Duda

Medical Centers

  • Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.

  • Department of Pathology, Massachusetts General Hospital, Boston, MA

  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

Locations

  • United States

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Raf-1 proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Sorafenib

  • AZD-6244

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved